Laboratory of Clinical Biochemistry and Metabolism Dr. phil. U. Berger/Dr. med. Dr. sc. nat. A. Schumann University Children`s Hospital Breisacher Str. 62 79106 Freiburg Germany



Phone: +49- 761- 270- 43680
Switchboard: +49- 761- 270- 43000
Fax: +49- 761- 270- 9645270
E-Mail: zkj.stoffwechsellabor@list.uniklinik-freiburg.de

Request form

University Children's Hospital
Department of Pediatrics and
Adolescent Medicine
Prof. Dr. med. U. Spiekerkötter
Chair and Medical Director of Pediatrics

(Muscular) hypotonia Recurrent vomitting Sender (name, full postal address)	Name of referring physician (block letters) Phone E-Mail address Date/Signature					
	□ no □ yes (please specify) □ no □ yes (please specify) Pathological findings: Acidosis [pH, BE] Anion gap [mmol/l] CK [U/l] Hyperammonaemia [μmol/l] Hypoglycaemia [mg/dl] Ketonuria Lactic acidaemia [mmol/l] Liver enzymes [U/l] Miscellaneous: □					
Date of sample collection: Clinical information/diagnostic indications (essential for interpretation of test results)						
Date of birth: Gender:						
Patient data (block letters) Name: First name:						

Revision: 001/23.09.2024 1/3 Dok.-ID.: 115905

Metabolic requests: ☐ Basic screening: Acylcarnitines (DB), amino acids (S)¹, organic acids (U)⁴, simple metabolic tests (U)⁴					
Special requests:					
 Acylcarnitines (DB) Acylcarnitines (S)¹ Acylcarnitines (U)⁴ Adenosindesaminase 2 (ADA 2)-activity (WB)³.5,9 (Require S-Adenosylmethionine/S-Adenosylhomocysteine (SAM/S Alpha-aminoadipate semialdehyde (U)⁴.8 Amino acids quantitative (CSF)¹.7 Amino acids quantitative (S)¹ Amino acids quantitative (U)⁴ CDG-diagnostics (S)¹ 7-Dehydrocholesterol (S)¹ Enantiomeric separation (□ Glyceric acid, □ 2-Hydroxy-g Fatty-acid oxidation: 	AH) (P) ^{2,7}				
☐ Enzymatics (WB) ^{3,5,9} (Requires declaration of consent ☐ MCAD ☐ VLCAD	on page 3)				
· · · · · · · · · · · · · · · · · · ·	transporter (OCTN2) FFA; ETFB; ETFDH)	□ CPT 1 (<i>CPT1A</i>) □ LCHAD/MTP (<i>HADHA; HADH</i>) □ VLCAD (<i>ACADVL</i>)			
☐ Homocysteine (S/P)¹					
☐ Creatine deficiency syndromes (U) ⁴					
 Lysosomal diagnostics: □ Fabry disease (DB⁶, only after consultation!) □ Gaucher disease (DB⁶, only after consultation!) □ Mucopolysaccharidosis: □ Screening assay (U)⁴ □ Electrophoresis (U)⁴ □ Enzymatics (Type I, II, IIIB, IVA, VI, VII), (DB⁶, only □ Niemann-Pick disease (DB⁶, only after consultation!) □ Pompe disease (DB⁶, only after consultation!) □ Wolman disease (DB⁶, only after consultation!) □ Methylmalonic acid (S/U)^{2,4} □ Mono-/Disaccharides (U)⁴ □ Organic acids (U)⁴ □ Orotic acid (U)⁴ □ Peroxisomal disorders (VLCFA, Phytanic acid) (S)² □ Phenylalanine-/Tyrosine concentration (DB) □ Purines-/Pyrimidines (U)⁴ □ Remethylation defects: □ Enzymatics (CbIC, CBS, MTHFR), only after consulation (Discovate) □ Remethylation profile (homocysteine, cysteine, methods) □ Sulfocysteine (U)^{4,7} 	ıltation!	(P/U) ^{1,4}			
Legend for requested tests:					
(CSF) Cerebrospinal fluid (DB) Dried blood spots (allow to dry for 2 hrs at rt) (F) Fibroblasts (P) EDTA-plasma (S) Serum (U) Urine, conservation with 4-6 drps. of dichloromethane, ship at rt (WB) EDTA whole blood	6. At no charge throug 7. Immediately transfe 8. Store at -20 C° unti frozen specimen toge 9. Arrival within 48 h	nandatory (German law § 8, Abs. 1) gh different diagnostic initiatives er to and ship on dry ice I shipment, shipment of the ther with cold pack after blood draw at the latest ics only after consultation			

Declaration of consent for enzymatic testing according to the *German Genetic Diagnostics Act (GenDG)*



Facility/Phys	sician/Stamp	Patient da	ta
		Name:	Date of birth:
		First name	:
		Street/num	ber:
		Postcode/p	place:
analyses. Gen on the question	etic counseling is additional n, high-throughput methods	lly required prior to prenatal and such as exome sequencing are	itten consent for all molecular genetic predictive (predictive) analyses. Depending also used. According to the <i>German Genetic</i> as biochemical/enzymatic tests.
Desired analys	sis/question (diagnosis, gen	e or biochemical-enzymatic inve	stigation):
Please read th	is consent carefully and ma	ork the answers that apply to you	:
O I consent to	the findings of the analysis((s) being forwarded to Dr.:	
O If necessary	, my findings/ may be used	for the consultation/ examination	of the following relatives:
molecular gendata. I have be genetic/bioche The possible of family member in whole or in phave been info	etic/biochemical/enzymatic een informed about the purp emical/enzymatic analysis al consequences of the results rs were also discussed in de part at any time without giving	methods and consent to the processe, nature, extent and significand have had sufficient opportunit of the molecular genetic/biocheretail (genetic counseling). I have ng reasons, either orally or in wri	It to be examined for genetic changes using cessing of the genetic sample and genetic note of the requested molecular y to discuss any open questions. mical/enzymatic analysis for me or other been informed that I may revoke my consent ting, without incurring any disadvantages. I he examination in whole or in part, but to have
Please mark w	vith a cross where applicable	e:	
request that m O The results so that they ma O I agree to th laboratory-ana O I agree that	edically significant incidenta of the examinations do not l ay also be available to my fa e storage of the examinatio alytical quality control measu	al findings be reported. have to be destroyed after 10 yea amily at a later date if necessary n material for possible additional ures. se in question may be used in en	ove diagnosis (incidental findings). I also ars in accordance with the legal requirements examinations to find a diagnosis or for crypted form (pseudonymized) for scientific
		Signature of patient or le	
Place, date		Signature of informing ph	

Revision: 001/23.09.2024 3/3 Dok.-ID.: 115905